The Goldman Sachs Future Health Care Equity ETF (GDOC) gained momentum after positive news from its largest holding, Eli Lilly (LLY), whose price target was raised by JPMorgan. GDOC has returned 11.8% over the past three months, recovering from earlier underperformance in 2026. The fund invests actively in innovative healthcare firms, focusing on genomics, precision medicine, and digital health, and benefits from potential tailwinds like future interest rate cuts and increased M&A activity. Another key holding, Johnson & Johnson, also contributed with nearly 30% returns year-to-date and recent FDA approval for a cardiac catheter. GDOC is well-positioned for growth in the second half of the year as healthcare innovation and economic improvements drive demand.
Nxera Pharma announced a net profit of JPY 1,591 million (US$10.1 million) for Q2 2026, reversing a prior loss due to multiple milestone payments from partners like Neurocrine, AbbVie, and Lilly. The company progressed regulatory approvals and commer...
Eli Lilly and Novo Nordisk both beat Q2 estimates and raised their full-year outlooks, but investors favored Lilly, boosting its shares while punishing Novo. Lilly leads the obesity drug market with a 60.9% U.S. share, driven by strong sales of Mounj...
Eli Lilly reported strong Q2 results with robust revenue growth led by key drugs Mounjaro and Zepbound. The company raised its 2026 revenue guidance to $85–87 billion, supported by volume gains despite price declines, and expects continued margin exp...
Eli Lilly reported a 48% year-on-year revenue increase to $22.97 billion, driven by strong sales of GLP-1 drugs Mounjaro and Zepbound, which make up about 65% of total revenue. The company raised its 2026 revenue guidance to $85 billion–$87 billion, ...
The Dow Jones surged 650 points to a new high of 54,740, and the S&P 500 also reached an all-time high, rising 0.7% to 7,790. However, tech stocks showed weakness with the Nasdaq up only 0.35%, dragged down by a 10% plunge in SpaceX shares after its ...
